Company news
CVRx, Inc. news in 2026
CVRx, Inc.'s news releases, calls and decks from 2026, newest first.
CVRx to Participate in Upcoming Investor Conferences
November 2, 2026
CVRx to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call on November 5, 2026
October 22, 2026
CVRx Announces Late-Breaking Data and New Clinical Evidence on Barostim at the HFSA Annual Scientific Meeting 2026
September 29, 2026
CVRx Appoints John Landry as Chief Financial Officer
September 21, 2026
CVRx Responds to Letter from Pointillist Family Office
August 25, 2026
Jorey Chernett, Owner of More than 5.5% of Outstanding Shares of CVRx, Calls on Board to Begin Immediate Process to Pursue Sale of the Company to a Strategic Acquirer
August 24, 2026
CVRx Announces Devoted Health Medicare Advantage Coverage Policy for Barostim Therapy
August 24, 2026
CVRx Announces Sales Leadership Transition
August 11, 2026
Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q)
August 6, 2026
CVRx Reports Second Quarter 2026 Financial and Operating Results
August 6, 2026
CVRx to Present at Canaccord Genuity's 46th Annual Growth Conference
July 28, 2026
CVRx to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call on August 6, 2026
July 23, 2026
CVRx Announces Chief Financial Officer Transition
June 8, 2026
CVRx to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
May 27, 2026
CVRx to Present at the William Blair 46th Annual Growth Stock Conference
May 20, 2026
CVRx Announces Humana Medicare Advantage Coverage Policy for Barostim Therapy
May 13, 2026
CVRx Reports First Quarter 2026 Financial and Operating Results
May 11, 2026
CVRx Announces First Patient Enrollment in BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population
May 4, 2026
CVRx to Report First Quarter 2026 Financial and Operating Results and Host Conference Call on May 11, 2026
April 27, 2026
CVRx Announces Nomination of Michael Dale for Election to the Board of Directors
April 20, 2026
CVRx Reports Preliminary First Quarter 2026 Financial Results
April 13, 2026
CVRx Announces Late-Breaking Data and Scientific Presentations Highlighting Barostim Outcomes at the THT 2026 Annual Meeting
March 2, 2026
CVRx Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
February 12, 2026
CVRx to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call on February 12, 2026
January 29, 2026
CVRx Announces Initiation of BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population
January 22, 2026
CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2025 Financial Results and Issues Fiscal 2026 Guidance
January 12, 2026
CVRx Announces Implementation of New Category I CPT Codes for Barostim Therapy
January 6, 2026